WCM
MYGN icon

Wedge Capital Management’s Myriad Genetics MYGN Stock Holding History

Wedge Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-30,273
Closed -$623K – 582
2016
Q3 		$623K Buy
+30,273
New +$768K 0.01% 398
2014
Q2 		– Sell
-7,850
Closed -$268K – 584
2014
Q1 		$268K Buy
+7,850
New +$243K ﹤0.01% 462

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wedge Capital Management's MYGN Position: Q4 2016 in Review

Wedge Capital Management sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 30,273 shares — an estimated $623K sold.

Wedge Capital Management first reported a position in MYGN in Q1 2014 and held it in 2 quarters. The position peaked at $623K in Q3 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

  • Wedge Capital Management reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
  • Wedge Capital Management sold 30,273 Myriad Genetics shares in Q4 2016, an estimated $623K.
  • Wedge Capital Management first reported a position in Myriad Genetics in Q1 2014 and held it in 2 quarters.
  • Wedge Capital Management's Myriad Genetics position peaked at $623K in Q3 2016.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Wedge Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.